Stevens Capital Management LP lowered its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 17.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,048 shares of the biotechnology company’s stock after selling 4,118 shares during the period. Stevens Capital Management LP’s holdings in BioMarin Pharmaceutical were worth $1,866,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of BioMarin Pharmaceutical by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock valued at $1,302,816,000 after buying an additional 642,623 shares in the last quarter. Jennison Associates LLC increased its position in shares of BioMarin Pharmaceutical by 33.8% in the 2nd quarter. Jennison Associates LLC now owns 13,242,773 shares of the biotechnology company’s stock valued at $1,202,709,000 after buying an additional 3,348,168 shares in the last quarter. TIAA CREF Investment Management LLC increased its position in shares of BioMarin Pharmaceutical by 63.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock valued at $204,437,000 after buying an additional 875,686 shares in the last quarter. Manning & Napier Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 25.2% in the 2nd quarter. Manning & Napier Advisors LLC now owns 2,118,486 shares of the biotechnology company’s stock valued at $192,399,000 after buying an additional 426,016 shares in the last quarter. Finally, Pictet Asset Management Ltd. increased its position in shares of BioMarin Pharmaceutical by 17.0% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,134,622 shares of the biotechnology company’s stock valued at $105,599,000 after buying an additional 164,788 shares in the last quarter. Institutional investors and hedge funds own 97.39% of the company’s stock.

Shares of BioMarin Pharmaceutical Inc. (BMRN) opened at $82.03 on Friday. BioMarin Pharmaceutical Inc. has a one year low of $79.50 and a one year high of $100.51. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The business had revenue of $334.18 million during the quarter, compared to the consensus estimate of $347.38 million. During the same period last year, the business posted $0.02 EPS. BioMarin Pharmaceutical’s revenue was up 19.4% on a year-over-year basis. sell-side analysts expect that BioMarin Pharmaceutical Inc. will post -0.66 EPS for the current fiscal year.

In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 3,750 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $91.26, for a total transaction of $342,225.00. Following the completion of the sale, the director now directly owns 19,660 shares in the company, valued at $1,794,171.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Robert Ajer sold 3,521 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $95.00, for a total transaction of $334,495.00. Following the sale, the executive vice president now owns 49,299 shares of the company’s stock, valued at $4,683,405. The disclosure for this sale can be found here. Insiders have sold 40,686 shares of company stock valued at $3,736,318 over the last 90 days. Company insiders own 1.85% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/biomarin-pharmaceutical-inc-bmrn-position-lowered-by-stevens-capital-management-lp/1698026.html.

A number of research firms recently commented on BMRN. BidaskClub cut shares of BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Stifel Nicolaus reiterated a “buy” rating and set a $107.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, August 4th. Wedbush reiterated a “neutral” rating and set a $108.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, August 7th. Evercore ISI began coverage on BioMarin Pharmaceutical in a report on Wednesday, August 16th. They set an “outperform” rating and a $100.00 target price for the company. Finally, Leerink Swann reiterated an “outperform” rating and set a $142.00 target price (up previously from $136.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the company’s stock. BioMarin Pharmaceutical currently has an average rating of “Hold” and an average target price of $111.55.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.